Ruxton Pharmaceuticals

Ruxton Pharmaceuticals is a biotechnology company focused on the development of novel small molecule therapeutics for neurological and psychiatric disorders. The company was established as a commercialization vehicle for research conducted at the Lieber Institute for Brain Development (LIBD), located on the Johns Hopkins Medical Campus. Ruxton leverages LIBD’s unique access to human brain tissue and genetic data to identify and validate novel drug targets for complex CNS conditions. Their lead research efforts involve the modulation of KCNQ potassium channels to address unmet needs in epilepsy and schizophrenia. By applying a precision medicine approach to neuroscience, Ruxton aims to translate genetic insights into transformative treatments for patients.